🟢 Moderna is trading 4.48% up today after Phase 3 trial met survival endpoints

Moderna is trading 4.48% up now at $190.74 as investors respond to positive Phase 3 melanoma results for intismeran autogene with Merck’s Keytruda.

• INTerpath-001 met its recurrence-free-survival primary endpoint and distant-metastasis-free-survival secondary endpoint.
• The company-specific rally extends gains from September 21 and September 22, ahead of detailed data expected at the October 24 ESMO Presidential Symposium.